Pharmacodynamic and pharmacokinetic interactions between simvastatin and diazepam in rats

被引:8
作者
Slupski, Wojciech [1 ]
Trocha, Malgorzata [1 ]
Rutkowska, Maria [1 ]
机构
[1] Wroclaw Med Univ, Dept Pharmacol, Wroclaw, Poland
关键词
Behavior; Anxiety; Drug interactions; Simvastatin; Diazepam; COA REDUCTASE INHIBITORS; ELEVATED PLUS-MAZE; HUMAN HEPATOCYTES; MAIN METABOLITE; P-GLYCOPROTEIN; ANXIETY; DOPAMINE; DEPRESSION; STATINS; BRAIN;
D O I
10.1016/j.pharep.2017.03.012
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Statins and benzodiazepines are widely used drugs, especially in ischemic heart disease, where exacerbation caused by anxiety can even lead to cardiac death. There have not been any reports of statin drug interaction with anxiolytics so far, but it is possible that these drugs interact with each other. We examined the effect of chronic oral administration of simvastatin on the anxiolytic activity and pharmacokinetics of diazepam in rats. Methods: Studies were conducted on male Wistar Han rats treated with simvastatin (2.5, 5, 10, 20 mg/kg) for 4-6 weeks, and/or diazepam (2.5, 5, 10 mg/kg) administered once on the day of the study. Evaluation of potential pharmacodynamic interaction was based on the behavioral tests: elevated plus maze (EPM) test and the Vogel conflict test (VCT). The assessment of the potential pharmacokinetic interaction was based on measurements of concentrations of diazepam and its metabolites in the blood of animals. Results: Diazepam 5 and 10 mg/kg given together with simvastatin 10 and 20 mg/kg showed no anxiolytic effect in the EPM test. In the VCT diazepam combinations with simvastatin did not produce any anxiolytic effect either, with an exception of the co-administration of diazepam 10 mg/kg and simvastatin 10 mg/kg. Simvastatin (20 mg/kg) significantly reduced the area under curve (AUC) of diazepam by 51.6% and temazepam by 54.6%. Conclusions: Abolition of diazepam anxiolytic effect during concomitant use of simvastatin is probably caused by diminished bioavailability of diazepam, although pharmacodynamic interaction between these drugs cannot be excluded. (c) 2017 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Sp. z o.o. All rights reserved.
引用
收藏
页码:943 / 952
页数:10
相关论文
共 45 条
  • [1] Anbinder Ana Lia, 2006, Braz. Dent. J., V17, P267, DOI 10.1590/S0103-64402006000400001
  • [2] HMG-CoA reductase inhibitors and P-glycoprotein modulation
    Bogman, K
    Peyer, AK
    Török, M
    Küsters, E
    Drewe, J
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (06) : 1183 - 1192
  • [3] NEUROMODULATORY ACTIONS OF DOPAMINE IN THE NEOSTRIATUM ARE DEPENDENT UPON THE EXCITATORY AMINO-ACID RECEPTOR SUBTYPES ACTIVATED
    CEPEDA, C
    BUCHWALD, NA
    LEVINE, MS
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (20) : 9576 - 9580
  • [4] LOWERING OF PLASMA-CHOLESTEROL LEVELS IN ANIMALS BY LOVASTATIN AND SIMVASTATIN
    CHAO, Y
    CHEN, JS
    HUNT, VM
    KURON, GW
    KARKAS, JD
    LIOU, R
    ALBERTS, AW
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1991, 40 : S11 - S14
  • [5] Choi DH, 2009, EUR J DRUG METAB PH, V34, P163
  • [6] Comparison of midazolam and simvastatin as cytochromc P450 3A probes
    Chung, E
    Nafziger, AN
    Kazierad, DJ
    Bertino, JS
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2006, 79 (04) : 350 - 361
  • [7] Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes
    Cohen, LH
    van Leeuwen, REW
    van Thiel, GCF
    van Pelt, JF
    Yap, SH
    [J]. BIOPHARMACEUTICS & DRUG DISPOSITION, 2000, 21 (09) : 353 - 364
  • [8] EFFECTS OF BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONISTS IN THE ELEVATED PLUS-MAZE TEST OF ANXIETY IN THE RAT
    COLE, BJ
    HILLMANN, M
    SEIDELMANN, D
    KLEWER, M
    JONES, GH
    [J]. PSYCHOPHARMACOLOGY, 1995, 121 (01) : 118 - 126
  • [9] Collins R, 2002, LANCET, V360, P7, DOI 10.1016/S0140-6736(02)09327-3
  • [10] Molecular targets for the myorelaxant action of diazepam
    Crestani, F
    Löw, K
    Keist, R
    Mandelli, MJ
    Möhler, H
    Rudolph, U
    [J]. MOLECULAR PHARMACOLOGY, 2001, 59 (03) : 442 - 445